05:15 PM EDT, 06/26/2025 (MT Newswires) -- ProQR Therapeutics ( PRQR ) said late Thursday it has filed an application to the European Medicines Agency to start a phase 1 trial of AX-0810 targeting NTCP, a liver cell protein that carries bile acids into cells.

The trial will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers, with initial data expected in Q4 2025, the company said.

The shares were rising about 6% in after-hours activity.